Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 327.54B |
| Revenue (ttm) | 82.47B |
| Net Income (ttm) | 20.13B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 16.27 |
| Forward PE | 14.62 |
| Dividend | 4.62 (3.44%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 4,311 |
| Average Volume | 3,739 |
| Open | 134.62 |
| Previous Close | 134.30 |
| Day's Range | 134.30 - 136.68 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | n/a |
| RSI | 49.22 |
| Earnings Date | Jul 16, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, ‘No More Tears' author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, No More Tears author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
Tech stocks struggle while healthcare gains: Today's market overview
Tech stocks struggle while healthcare gains: Today's market overview The US stock market is showcasing a dynamic landscape today, characterized by struggles within the semiconductor sector and encoura...
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBC's Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A ou...
J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBCs Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A out...
Watch CNBC's full interview with Johnson & Johnson chairman and CEO Joaquin Duato
CNBCs Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A out...
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executiv...
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaq...
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)
P/E Ratio Insights for Johnson & Johnson
In the current market session, Johnson & Johnson Inc. (NYSE: JNJ) share price is at $153.53, after a 0.19% increase. Moreover, over the past month, the stock decreased by 1.78% , but in the past year...
Why Dan Loeb Just Made Kenvue One Of His Top Holdings
Activist investor Dan Loeb‘s Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. (NYSE: KVUE) in the first quarter of 2025 . Kenvue was formerly a part of Johnson & Jo...
Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued
Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth
No Rolex For Me - I'm Buying Dividends That Pay For Life
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable ...
Tech sector struggles, financial and healthcare remain resilient
Today’s stock market reveals a challenging environment for technology stocks, with mixed outcomes across financial and healthcare sectors. Investors witness a dynamic trading landscape, highlighting t...
FDA Panel Reiterates the Cancer Risks of Talc
A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice a...
FDA Panel Reiterates the Cancer Risks of Talc
WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer produc...
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Easte...
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate...
US stocks tumble. Yields start to weigh on the equities
U.S. equities have reversed sharply into negative territory amid a surge in Treasury yields, following a disappointing 20-year bond auction. The Dow Jones Industrial Average is down 684 points (-1.61%...
Forget About Dividend Yield, Do This Instead
Focus on dividend sustainability and business quality, not just high yield, to build reliable passive income. Avoid overexposure to cyclical sectors; prioritize companies with resilient dividends thro...
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or ...